Article Details
Retrieved on: 2018-04-24 20:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>The Rivelin® patch incorporates clobetasol propionate to treat OLP and is planned to commence a clinical Phase 2b study in 2018. Shareholders include <b>Sofinnova Ventures</b>, Lundbeckfonden Emerge, Novo Seeds and Welfare Tech Invest. For additional information, please visit www.dermtreat.com.</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here